[Skip to Navigation]
Special Article
June 28, 2010

By Jove! What Is a Clinician to Make of JUPITER?

Author Affiliations

Author Affiliations: Division of Cardiology (Drs Kaul and Diamond) and Department of Medicine (Dr Morrissey), Cedars-Sinai Medical Center, Los Angeles, California.

Arch Intern Med. 2010;170(12):1073-1077. doi:10.1001/archinternmed.2010.189

By Jove, I always took three threes for nine.—William Shakespeare, Love's Labours Lost (1588)

On February 9, 2010, the US Food and Drug Administration (FDA) extended its approval of rosuvastatin to include the indication for reducing the risk of stroke, myocardial infarction (MI), and revascularization procedures in individuals who have normal low-density lipoprotein cholesterol (LDL-C) levels and no clinically evident coronary heart disease but have an increased risk based on age, high-sensitivity C-reactive protein (hsCRP) levels, and the presence of at least 1 additional cardiovascular disease risk factor.1 The decision by the FDA was based on results from the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study, which demonstrated a 44% risk reduction in the primary end point in 17 802 primary prevention patients randomly allocated to treatment with rosuvastatin, 20 mg, compared with placebo.2